M

Mass General Brigham

Early-stage life science venture investor

Research Administrative Director

Full-TimeUpdated on 10/23/2026
$124.3k - $180.9k/yr+ Bonuses + Differentials
Senior
Bachelor's, Master's
Boston, MA, USA
HybridHybrid role; work location is 40 Blossom Street.
Business & StrategyBusiness Operations

About the job

Requirements
  • A bachelor's degree in management, finance, or a related discipline is required; a master's degree is preferred.
  • At least 5 to 7 years of directly related management experience within research settings is required.
  • Research or technical experience in an academic environment is a plus.
  • Extensive knowledge of research financial and operational matters, business planning, project management, grant management, and sponsor and institutional guidelines and requirements is required.
  • The role requires effective financial and analytical skills, including the ability to develop and monitor budgets and manage grants and contracts.
  • The role requires the ability to ensure timely submission and review of budgets and performance evaluations.
  • The role requires exceptional organizational skills and the ability to organize time and priorities effectively.
  • The role requires the ability to handle sensitive issues confidentially and in accordance with institutional guidelines.
  • The role requires the ability to develop a common vision for stakeholders, communicate effectively, gain support for ideas, and take ownership of activities.
  • The role requires interpersonal skills to work effectively with senior management and staff, and strong verbal and written communication skills to communicate complex material.
  • The role requires experience in strategic development and team building, an independent approach, and the ability to handle multiple tasks and competing deadlines.
  • The role requires the ability to evaluate complex situations, make timely decisions independently, and know when additional input is needed.
  • The role requires extensive knowledge of research management and administration, strategic development, budgeting and financial projections, and contracts and negotiation.
  • The role requires strong computer skills, including fund management systems such as Insight and Strata, databases such as RedCap, Microsoft Office applications, MGB enterprise systems such as Insight and Workday, and other office management systems.
  • The role requires the ability to recruit, train, and supervise staff, and experience mentoring middle managers.
  • The role requires experience supporting, directing, and developing staff.
  • The role requires the ability to identify and distill complex issues, develop creative solutions, and implement them.
  • The role requires the ability to manage day-to-day operations and establish and maintain policies and procedures.
  • The role requires sensitivity to cultural differences and lived experiences, and the ability to adapt communication accordingly.
Responsibilities
  • Assist in establishing and operationalizing strategic priorities for research, faculty recruitment and retention, education, and fundraising.
  • Supervise the budgetary process, including reviewing and approving funding requests, and serve as liaison to the Development Office by providing strategic guidance and involvement in fundraising.
  • Perform funding analyses, including forecasting anticipated deficits and surpluses.
  • Oversee management of symposia and visits and lectures by outside researchers in areas relevant to stem cell research.
  • Develop and implement tools, systems, and resources to support proposal and award activities and improve coordination of grant activities among principal investigators and Research Management.
  • Work with Research Management and principal investigators to ensure continuity of the overall research effort.
  • Manage all phases of research grant and contract administration, including personnel management and staff training and development.
  • Oversee and approve research financial transactions, including payroll, travel requests, employee changes, journal entries, and check requests; oversee research expense management at divisional and laboratory levels; perform comparative analyses; and develop and implement cost-containment policies, procedures, and strategies.
  • Set administrative direction and coordinate research activities for the Center in collaboration with the Center Director and faculty.
  • Manage the Center’s day-to-day operations and strategic initiatives that support its mission.
  • Oversee research administration, including grant administration, research compliance, procurement, data transfer and storage, and contracting, in alignment with the Center’s scientific objectives and mission.
  • Develop and implement program activities to advance the Center’s research mission and efficient operations.
  • Lead an administrative staff group addressing the needs of the Center, researchers, and research staff.
  • Create, improve, and sustain best practices to drive continuous improvement.
  • Ensure compliance with research policies and procedures consistent with MGB, Harvard Medical School, and government guidelines, and communicate policy changes to principal investigators, grant administrators, and staff.
  • Monitor the Center’s funding portfolio, prepare fiscal projection reports, and advise on funding strategies and initiatives that support its fiscal health.
  • Review transactions for compliance and approve as appropriate, including grant proposals, procurement transactions, fiscal support requests, space utilization reports, and asset records.
  • Evaluate staffing needs and operations to ensure appropriate staffing levels for faculty and professional roles and staff positions.
  • Lead staff management, including onboarding and training, workload allocation, prioritization, performance reviews, and corrective action.
  • Stay current on personnel-related issues such as benefits, maternity leave, FMLA, UKG, and Workday, and develop and oversee Center policies to support compliance and staff wellbeing.
  • Identify opportunities for staff professional development and implement employee retention strategies to support engagement and productivity.
  • Oversee activities of ancillary research personnel, including non-employees, persons of interest, contractors, affiliates, and interns.
  • Attend meetings outside regularly scheduled hours when required.
Desired Qualifications
  • Research or technical experience in an academic environment.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.